Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 232

Similar articles for PubMed (Select 23943781)

1.

Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization.

Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, Neal JW, Love S, Nicoll JA, Boche D.

Brain. 2013 Sep;136(Pt 9):2677-96. doi: 10.1093/brain/awt210. Epub 2013 Aug 13.

2.

Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.

Serrano-Pozo A, William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA, Hock C, Nitsch RM, Masliah E, Growdon JH, Frosch MP, Hyman BT.

Brain. 2010 May;133(Pt 5):1312-27. doi: 10.1093/brain/awq056. Epub 2010 Mar 31.

3.

Effect of active Aβ immunotherapy on neurons in human Alzheimer's disease.

Paquet C, Amin J, Mouton-Liger F, Nasser M, Love S, Gray F, Pickering RM, Nicoll JA, Holmes C, Hugon J, Boche D.

J Pathol. 2015 Apr;235(5):721-30. doi: 10.1002/path.4491. Epub 2015 Jan 7.

PMID:
25430817
4.

Microglial alterations in human Alzheimer's disease following Aβ42 immunization.

Zotova E, Holmes C, Johnston D, Neal JW, Nicoll JA, Boche D.

Neuropathol Appl Neurobiol. 2011 Aug;37(5):513-24. doi: 10.1111/j.1365-2990.2010.01156.x.

PMID:
21166690
5.

Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA.

Brain. 2008 Dec;131(Pt 12):3299-310. doi: 10.1093/brain/awn261. Epub 2008 Oct 25.

6.

CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation.

Obregon D, Hou H, Bai Y, Nikolic WV, Mori T, Luo D, Zeng J, Ehrhart J, Fernandez F, Morgan D, Giunta B, Town T, Tan J.

Neurobiol Dis. 2008 Feb;29(2):336-53. Epub 2007 Oct 16.

7.

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.

Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, Watts RJ.

J Neurosci. 2012 Jul 11;32(28):9677-89. doi: 10.1523/JNEUROSCI.4742-11.2012.

8.

Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease.

Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C, Nicoll JA.

Acta Neuropathol. 2010 Jul;120(1):13-20. doi: 10.1007/s00401-010-0705-y. Epub 2010 Jun 9.

PMID:
20532897
9.

Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease.

Zhang YH, Raymick J, Sarkar S, Lahiri DK, Ray B, Holtzman D, Dumas M, Schmued LC.

Curr Alzheimer Res. 2013 Jun;10(5):494-506.

PMID:
23627708
10.

Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease.

Streit WJ, Braak H, Xue QS, Bechmann I.

Acta Neuropathol. 2009 Oct;118(4):475-85. doi: 10.1007/s00401-009-0556-6. Epub 2009 Jun 10.

11.

Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro.

Veerhuis R, Van Breemen MJ, Hoozemans JM, Morbin M, Ouladhadj J, Tagliavini F, Eikelenboom P.

Acta Neuropathol. 2003 Feb;105(2):135-44. Epub 2002 Nov 6.

PMID:
12536224
12.

Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q.

Webster SD, Galvan MD, Ferran E, Garzon-Rodriguez W, Glabe CG, Tenner AJ.

J Immunol. 2001 Jun 15;166(12):7496-503.

13.

Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease.

Ferrer I, Boada Rovira M, Sánchez Guerra ML, Rey MJ, Costa-Jussá F.

Brain Pathol. 2004 Jan;14(1):11-20.

PMID:
14997933
15.

Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.

Bergamaschini L, Canziani S, Bottasso B, Cugno M, Braidotti P, Agostoni A.

Clin Exp Immunol. 1999 Mar;115(3):526-33.

17.

An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.

Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T.

J Neurosci. 2004 Jul 14;24(28):6277-82.

18.

Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers.

Hjorth E, Zhu M, Toro VC, Vedin I, Palmblad J, Cederholm T, Freund-Levi Y, Faxen-Irving G, Wahlund LO, Basun H, Eriksdotter M, Schultzberg M.

J Alzheimers Dis. 2013;35(4):697-713. doi: 10.3233/JAD-130131.

PMID:
23481688
19.

Pathological relationships between microglial cell activity and tau and amyloid beta protein in patients with Alzheimer's disease.

Hayes A, Thaker U, Iwatsubo T, Pickering-Brown SM, Mann DM.

Neurosci Lett. 2002 Oct 18;331(3):171-4.

PMID:
12383924
20.

'Clinical trials in Alzheimer's disease': immunotherapy approaches.

Delrieu J, Ousset PJ, Caillaud C, Vellas B.

J Neurochem. 2012 Jan;120 Suppl 1:186-93. doi: 10.1111/j.1471-4159.2011.07458.x. Epub 2011 Nov 28. Review.

PMID:
21883222
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk